Movement Alert｜PegBio Rises 7.54% in Regular Trading, Rebounding After Pullback as GLP-1 Drug Commercialization Momentum Continues

Market Focus

May 22

On May 22, PegBio Co Ltd (02565.HK) rose 7.54% in regular trading, trading at HK$14.59/share with trading volume of HK$46.84 million, rebounding after a 5.14% decline in the prior session.

The stock continues to trade with elevated volatility following an explosive surge of over 100% on May 18, driven by accelerating commercialization of its GLP-1 drug Paidakang (vipetnapeptide injection). PegBio previously announced a strategic partnership with Tenry Pharma granting exclusive commercialization rights for Paidakang in mainland China, with a cumulative sales target exceeding RMB 10 billion and upfront royalty payments of approximately HK$140 million. Additionally, Tenry Pharma signed a cooperation agreement with Ark Health on May 12 for the online debut of the drug on its internet hospital platform.

PegBio is a biotechnology company focused on developing innovative therapies for chronic metabolic diseases. Its core product PB-119, a once-weekly long-acting GLP-1 receptor agonist approved in November 2025, targets type 2 diabetes and obesity markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106725922"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106725922\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106725922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 11:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106725922","market":"us","top_or_hot":-1,"title":"Movement Alert｜PegBio Rises 7.54% in Regular Trading, Rebounding After Pullback as GLP-1 Drug Commercialization Momentum Continues","media":"Market Focus","content":"<p><p>On May 22, PegBio Co Ltd (02565.HK) rose 7.54% in regular trading, trading at HK$14.59/share with trading volume of HK$46.84 million, rebounding after a 5.14% decline in the prior session.</p><p>The stock continues to trade with elevated volatility following an explosive surge of over 100% on May 18, driven by accelerating commercialization of its GLP-1 drug Paidakang (vipetnapeptide injection). PegBio previously announced a strategic partnership with Tenry Pharma granting exclusive commercialization rights for Paidakang in mainland China, with a cumulative sales target exceeding RMB 10 billion and upfront royalty payments of approximately HK$140 million. Additionally, Tenry Pharma signed a cooperation agreement with Ark Health on May 12 for the online debut of the drug on its internet hospital platform.</p><p>PegBio is a biotechnology company focused on developing innovative therapies for chronic metabolic diseases. Its core product PB-119, a once-weekly long-acting GLP-1 receptor agonist approved in November 2025, targets type 2 diabetes and obesity markets.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Rises 7.54% in Regular Trading, Rebounding After Pullback as GLP-1 Drug Commercialization Momentum Continues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Rises 7.54% in Regular Trading, Rebounding After Pullback as GLP-1 Drug Commercialization Momentum Continues\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-22 11:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 22, PegBio Co Ltd (02565.HK) rose 7.54% in regular trading, trading at HK$14.59/share with trading volume of HK$46.84 million, rebounding after a 5.14% decline in the prior session.</p><p>The stock continues to trade with elevated volatility following an explosive surge of over 100% on May 18, driven by accelerating commercialization of its GLP-1 drug Paidakang (vipetnapeptide injection). PegBio previously announced a strategic partnership with Tenry Pharma granting exclusive commercialization rights for Paidakang in mainland China, with a cumulative sales target exceeding RMB 10 billion and upfront royalty payments of approximately HK$140 million. Additionally, Tenry Pharma signed a cooperation agreement with Ark Health on May 12 for the online debut of the drug on its internet hospital platform.</p><p>PegBio is a biotechnology company focused on developing innovative therapies for chronic metabolic diseases. Its core product PB-119, a once-weekly long-acting GLP-1 receptor agonist approved in November 2025, targets type 2 diabetes and obesity markets.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1106725922","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106725922","pubTimestamp":1779420315,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 22, PegBio Co Ltd (02565.HK) rose 7.54% in regular trading, trading at HK$14.59/share with trading volume of HK$46.84 million, rebounding after a 5.14% decline in the prior session.The stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"动静提示|派格生物常规交易涨7.54%，GLP-1药物商业化势头延续，回调后反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On May 22, PegBio Co Ltd (02565.HK) rose 7.54% in regular trading, trading at HK$14.59/share with trading volume of HK$46.84 million, rebounding after a 5.14% decline in the prior session.The stock continues to trade with elevated volatility following an explosive surge of over 100% on May 18, driven by accelerating commercialization of its GLP-1 drug Paidakang (vipetnapeptide injection). PegBio previously announced a strategic partnership with Tenry Pharma granting exclusive commercialization rights for Paidakang in mainland China, with a cumulative sales target exceeding RMB 10 billion and upfront royalty payments of approximately HK$140 million. Additionally, Tenry Pharma signed a cooperation agreement with Ark Health on May 12 for the online debut of the drug on its internet hospital platform.PegBio is a biotechnology company focused on developing innovative therapies for chronic metabolic diseases. Its core product PB-119, a once-weekly long-acting GLP-1 receptor agonist approved in November 2025, targets type 2 diabetes and obesity markets.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}